Method of using NAP-2 and TGF-α to improve cardiac function
US12357676B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2022 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Aug 7, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.